JP2023503899A5 - - Google Patents

Info

Publication number
JP2023503899A5
JP2023503899A5 JP2022529453A JP2022529453A JP2023503899A5 JP 2023503899 A5 JP2023503899 A5 JP 2023503899A5 JP 2022529453 A JP2022529453 A JP 2022529453A JP 2022529453 A JP2022529453 A JP 2022529453A JP 2023503899 A5 JP2023503899 A5 JP 2023503899A5
Authority
JP
Japan
Application number
JP2022529453A
Other languages
Japanese (ja)
Other versions
JPWO2021102084A5 (https=
JP2023503899A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/061185 external-priority patent/WO2021102084A1/en
Publication of JP2023503899A publication Critical patent/JP2023503899A/ja
Publication of JPWO2021102084A5 publication Critical patent/JPWO2021102084A5/ja
Publication of JP2023503899A5 publication Critical patent/JP2023503899A5/ja
Priority to JP2025179403A priority Critical patent/JP2026021383A/ja
Pending legal-status Critical Current

Links

JP2022529453A 2019-11-22 2020-11-19 薬物送達のためのイオン液体 Pending JP2023503899A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025179403A JP2026021383A (ja) 2019-11-22 2025-10-24 薬物送達のためのイオン液体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939088P 2019-11-22 2019-11-22
US62/939,088 2019-11-22
PCT/US2020/061185 WO2021102084A1 (en) 2019-11-22 2020-11-19 Ionic liquids for drug delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025179403A Division JP2026021383A (ja) 2019-11-22 2025-10-24 薬物送達のためのイオン液体

Publications (3)

Publication Number Publication Date
JP2023503899A JP2023503899A (ja) 2023-02-01
JPWO2021102084A5 JPWO2021102084A5 (https=) 2023-11-28
JP2023503899A5 true JP2023503899A5 (https=) 2023-11-28

Family

ID=73835783

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022529453A Pending JP2023503899A (ja) 2019-11-22 2020-11-19 薬物送達のためのイオン液体
JP2025179403A Pending JP2026021383A (ja) 2019-11-22 2025-10-24 薬物送達のためのイオン液体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025179403A Pending JP2026021383A (ja) 2019-11-22 2025-10-24 薬物送達のためのイオン液体

Country Status (9)

Country Link
US (1) US20240016735A1 (https=)
EP (1) EP4061338A1 (https=)
JP (2) JP2023503899A (https=)
KR (1) KR20220104766A (https=)
CN (1) CN114980864A (https=)
AU (1) AU2020388387A1 (https=)
CA (1) CA3158963A1 (https=)
IL (1) IL293145A (https=)
WO (1) WO2021102084A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4329732A1 (en) * 2021-04-28 2024-03-06 Haleon US IP LLC Ionic liquid salts of active pharmaceutical ingredients
WO2022256291A1 (en) * 2021-06-01 2022-12-08 President And Fellows Of Harvard College Hydrogel devices for drug delivery to the ear
CN113637708B (zh) * 2021-08-09 2023-07-25 中国科学院过程工程研究所 一种CRISPR-cas9基因编辑系统递送载体及其制备方法和应用
CN118382429A (zh) 2021-10-08 2024-07-23 哈佛大学校长及研究员协会 用于药物递送的离子液体
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
CN114042032B (zh) * 2021-11-11 2024-04-26 武汉瑞佶生物科技有限公司 一种实现核酸皮肤递送的药物制剂及其制备方法和应用
CN114642733B (zh) * 2022-03-02 2023-08-22 中山大学 一种治疗雄激素源性脱发的组合物及其制备方法
CN118059118B (zh) * 2024-01-13 2025-07-22 张川 一种抑制nfkbiz基因表达的药物组合物和应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2658673A1 (en) 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
JP2008162899A (ja) * 2006-12-27 2008-07-17 Tokyo Univ Of Agriculture & Technology 生体関連化合物からなるイオン液体
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
JP6559394B2 (ja) * 2012-12-05 2019-08-14 ミヨシ油脂株式会社 親水性室温イオン液体とその用途
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
AU2013359262C1 (en) 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
CN105683376A (zh) 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
KR20250012194A (ko) 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
KR20160019553A (ko) 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
US10449254B2 (en) * 2013-11-03 2019-10-22 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
MX2016007325A (es) 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
WO2015168125A1 (en) 2014-04-28 2015-11-05 Recombinetics, Inc. Multiplex gene editing in swine
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
EP3686279B1 (en) 2014-08-17 2023-01-04 The Broad Institute, Inc. Genome editing using cas9 nickases
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016112242A1 (en) 2015-01-08 2016-07-14 President And Fellows Of Harvard College Split cas9 proteins
CN111918644A (zh) * 2017-11-17 2020-11-10 哈佛大学校长及研究员协会 用于内部递送的离子液体
EP3768240A4 (en) * 2018-03-19 2021-12-22 Cage Bio Inc. COMPOSITIONS OF IONIC LIQUID FOR THE TREATMENT OF ROSACEA
US20220257767A1 (en) * 2019-04-03 2022-08-18 President And Fellows Of Harvard College Ionic liquids for drug delivery

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2022527825A5 (https=)
BR112021014123A2 (https=)
JP2023503899A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)